CA2128331A1 - Methods for using histamine derivatives as immunomodulators and in immunotherapeutics - Google Patents

Methods for using histamine derivatives as immunomodulators and in immunotherapeutics

Info

Publication number
CA2128331A1
CA2128331A1 CA002128331A CA2128331A CA2128331A1 CA 2128331 A1 CA2128331 A1 CA 2128331A1 CA 002128331 A CA002128331 A CA 002128331A CA 2128331 A CA2128331 A CA 2128331A CA 2128331 A1 CA2128331 A1 CA 2128331A1
Authority
CA
Canada
Prior art keywords
histamine
chain
substituted
protein allergen
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002128331A
Other languages
English (en)
French (fr)
Inventor
Julia L. Greenstein
Kenneth L. Melmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2128331A1 publication Critical patent/CA2128331A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002128331A 1992-01-21 1993-01-19 Methods for using histamine derivatives as immunomodulators and in immunotherapeutics Abandoned CA2128331A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82322992A 1992-01-21 1992-01-21
US07/823,229 1992-01-21

Publications (1)

Publication Number Publication Date
CA2128331A1 true CA2128331A1 (en) 1993-07-22

Family

ID=25238155

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002128331A Abandoned CA2128331A1 (en) 1992-01-21 1993-01-19 Methods for using histamine derivatives as immunomodulators and in immunotherapeutics

Country Status (7)

Country Link
EP (1) EP0621780A1 (ja)
JP (1) JPH07503239A (ja)
CN (1) CN1078153A (ja)
AU (1) AU3591793A (ja)
CA (1) CA2128331A1 (ja)
MX (1) MX9300294A (ja)
WO (1) WO1993013772A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075845A2 (en) * 2003-02-24 2004-09-10 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
RS51840B (en) 2005-09-01 2012-02-29 Celgene Corporation IMMUNOLOGICAL APPLICATIONS OF IMMUNOMODULATORY UNITS FOR VACCINE AND FOR INFECTIOUS DISEASE THERAPY
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
EP3564671B1 (en) 2013-08-23 2021-09-29 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
US11352417B2 (en) 2016-12-22 2022-06-07 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
WO2018138607A1 (en) * 2017-01-24 2018-08-02 Nestec Sa Compositions comprising anti-fel d1 antibodies and methods for reducing at least one symptom of human allergy to cats

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996221A (en) * 1987-01-13 1991-02-26 The Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives as immune modulators

Also Published As

Publication number Publication date
AU3591793A (en) 1993-08-03
CN1078153A (zh) 1993-11-10
WO1993013772A1 (en) 1993-07-22
JPH07503239A (ja) 1995-04-06
EP0621780A1 (en) 1994-11-02
MX9300294A (es) 1994-01-31

Similar Documents

Publication Publication Date Title
JP4447657B2 (ja) 免疫寛容誘導剤
RU2236257C1 (ru) Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
ES2205231T3 (es) Procedimiento de tratamiento de la hipersensibilidad de tipo i que utilizan monofosforil lipido a.
JPH02501066A (ja) IgE非関与型疾病の治療方法および治療用ペプチド
Konturek et al. Antiulcer and gastroprotective effects of solon, a synthetic flavonoid derivative of sophoradin. Role of endogenous prostaglandins
Bartfeld et al. Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor.
US5556872A (en) Histamine derivatives useful as immunomodulators
US6699973B1 (en) Antibodies to peptides that target GIT receptors and related methods
CA2128331A1 (en) Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
JPH03151400A (ja) 化学修飾されたアレルゲン類およびそれらの調製方法
Ahlstedt et al. Specific antibody responses in rats and mice after daily immunization without adjuvant
Cara et al. Immunological induction of flavour aversion in mice. II. Passive/adoptive transfer and pharmacological inhibition
Fujimaki et al. Adjuvant effects of aluminum silicate on IgE and IgG1 antibody production in mice
Weinbaum et al. Comparison of cross-reactivities between albumins of various species at the level of antibody and helper T cells—studies in mice
US4702907A (en) Process for inducing selective immunosuppression of antibodies
Mitchell et al. Lung granulomatous hypersensitivity to eggs of Schistosoma japonicum in mice analysed by a radioisotopic assay and effects of hybridoma (idiotype) sensitization
Peri et al. Circulating antitoxin in rabbits after ingestion of diphtheria toxoid
Kemeny et al. Immune response to bee venom: II. Quantitation of the absolute amounts of IgE and IgG antibodies by saturation analysis
Galle et al. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation
WO1993014754A1 (en) Histamine derivatives and methods for their use as immunomodulators
JP2002249442A (ja) アレルギー減感作治療薬
RU2182492C1 (ru) Лекарственное средство для лечения наркотической зависимости
RU2548802C1 (ru) Иммуноген для лечения и профилактики зависимости от опиатов
Gamaleya et al. Induction of antibodies to morphine during chronic morphine treatment in rodents and opiate addicts
Wheeler et al. Adjuvant properties of hydrophobic derivatives prepared from L-tyrosine

Legal Events

Date Code Title Description
FZDE Dead